These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29721665)

  • 1. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.
    Sielaff CM; Mousa SA
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1205-1217. PubMed ID: 29721665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
    Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
    Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
    Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theranostic nanoparticles for detection and treatment of pancreatic cancer.
    Agarwal H; Bynum RC; Saleh N; Harris D; MacCuaig WM; Kim V; Sanderson EJ; Dennahy IS; Singh R; Behkam B; Gomez-Gutierrez JG; Jain A; Edil BH; McNally LR
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(4):e1983. PubMed ID: 39140128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
    Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
    Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
    Song H; Jiang C
    Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma.
    Xu B; Chen Y; Peng M; Zheng JH; Zuo C
    Int J Cancer; 2023 Jan; 152(2):110-122. PubMed ID: 35765844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells.
    Sanna V; Nurra S; Pala N; Marceddu S; Pathania D; Neamati N; Sechi M
    J Med Chem; 2016 Jun; 59(11):5209-20. PubMed ID: 27139920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision treatment of pancreatic ductal adenocarcinoma.
    Wei H; Ren H
    Cancer Lett; 2024 Mar; 585():216636. PubMed ID: 38278471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma.
    Castle J; Kotopoulis S; Forsberg F
    Methods Mol Biol; 2020; 2059():191-205. PubMed ID: 31435922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
    Mahajan UM; Teller S; Sendler M; Palankar R; van den Brandt C; Schwaiger T; Kühn JP; Ribback S; Glöckl G; Evert M; Weitschies W; Hosten N; Dombrowski F; Delcea M; Weiss FU; Lerch MM; Mayerle J
    Gut; 2016 Nov; 65(11):1838-1849. PubMed ID: 27196585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
    Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery.
    Liu X; Jiang J; Meng H
    Theranostics; 2019; 9(26):8018-8025. PubMed ID: 31754378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and Prospects in the Treatment of Pancreatic Cancer.
    Duan H; Li L; He S
    Int J Nanomedicine; 2023; 18():3973-3988. PubMed ID: 37489138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives.
    Oron Y
    Minerva Gastroenterol Dietol; 2015 Jun; 61(2):71-86. PubMed ID: 25610998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Landscapes to Drug Delivery Systems for the Treatment of Pancreatic Cancer.
    Magri A; Baveloni FG; de Camargo BAF; Chorilli M
    Curr Med Chem; 2021; 28(26):5411-5430. PubMed ID: 33745422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.